Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of MXN 5.22 trillion. The enterprise value is 5.85 trillion.
| Market Cap | 5.22T |
| Enterprise Value | 5.85T |
Important Dates
The last earnings date was Tuesday, February 3, 2026.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Dec 15, 2025 |
Share Statistics
| Current Share Class | 2.47B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.34% |
| Shares Change (QoQ) | -0.40% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 79.98% |
| Float | 2.47B |
Valuation Ratios
The trailing PE ratio is 15.89 and the forward PE ratio is 23.63.
| PE Ratio | 15.89 |
| Forward PE | 23.63 |
| PS Ratio | 4.46 |
| PB Ratio | 5.51 |
| P/TBV Ratio | 66.73 |
| P/FCF Ratio | 23.46 |
| P/OCF Ratio | 17.61 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.39, with an EV/FCF ratio of 26.28.
| EV / Earnings | 17.79 |
| EV / Sales | 5.17 |
| EV / EBITDA | 11.39 |
| EV / EBIT | 13.74 |
| EV / FCF | 26.28 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.96.
| Current Ratio | 1.54 |
| Quick Ratio | 0.96 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | 1.71 |
| Debt / FCF | 4.09 |
| Interest Coverage | 18.03 |
Financial Efficiency
Return on equity (ROE) is 36.88% and return on invested capital (ROIC) is 25.91%.
| Return on Equity (ROE) | 36.88% |
| Return on Assets (ROA) | 12.04% |
| Return on Invested Capital (ROIC) | 25.91% |
| Return on Capital Employed (ROCE) | 22.54% |
| Weighted Average Cost of Capital (WACC) | 5.35% |
| Revenue Per Employee | 15.82M |
| Profits Per Employee | 4.44M |
| Employee Count | 75,000 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.32 |
Taxes
In the past 12 months, Merck & Co. has paid 50.48 billion in taxes.
| Income Tax | 50.48B |
| Effective Tax Rate | 13.31% |
Stock Price Statistics
The stock price has increased by +12.52% in the last 52 weeks. The beta is 0.30, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +12.52% |
| 50-Day Moving Average | 1,966.28 |
| 200-Day Moving Average | 1,674.26 |
| Relative Strength Index (RSI) | 57.56 |
| Average Volume (20 Days) | 2,060 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.09 |
Income Statement
In the last 12 months, Merck & Co. had revenue of MXN 1.17 trillion and earned 328.63 billion in profits. Earnings per share was 131.06.
| Revenue | 1.17T |
| Gross Profit | 903.69B |
| Operating Income | 440.48B |
| Pretax Income | 379.27B |
| Net Income | 328.63B |
| EBITDA | 523.98B |
| EBIT | 440.48B |
| Earnings Per Share (EPS) | 131.06 |
Balance Sheet
The company has 262.22 billion in cash and 909.77 billion in debt, with a net cash position of -647.56 billion.
| Cash & Cash Equivalents | 262.22B |
| Total Debt | 909.77B |
| Net Cash | -647.56B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 948.08B |
| Book Value Per Share | 382.71 |
| Working Capital | 273.45B |
Cash Flow
In the last 12 months, operating cash flow was 296.55 billion and capital expenditures -74.03 billion, giving a free cash flow of 222.52 billion.
| Operating Cash Flow | 296.55B |
| Capital Expenditures | -74.03B |
| Free Cash Flow | 222.52B |
| FCF Per Share | n/a |
Margins
Gross margin is 77.21%, with operating and profit margins of 37.64% and 28.08%.
| Gross Margin | 77.21% |
| Operating Margin | 37.64% |
| Pretax Margin | 32.41% |
| Profit Margin | 28.08% |
| EBITDA Margin | 44.77% |
| EBIT Margin | 37.64% |
| FCF Margin | 19.01% |
Dividends & Yields
This stock pays an annual dividend of 61.71, which amounts to a dividend yield of 2.93%.
| Dividend Per Share | 61.71 |
| Dividend Yield | 2.93% |
| Dividend Growth (YoY) | 5.97% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 47.09% |
| Buyback Yield | 1.34% |
| Shareholder Yield | 4.25% |
| Earnings Yield | 6.29% |
| FCF Yield | 4.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Merck & Co. has an Altman Z-Score of 3.5 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.5 |
| Piotroski F-Score | 5 |